Clinical Trial Update: SMOFLipid in Patients Who Are Intralipid Intolerant [Phase 4]

View source ↗

Summary

A Phase 4 clinical trial evaluating SMOFLipid in patients intolerant to Intralipid for home parenteral nutrition or short bowel syndrome has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Short Bowel Syndrome

Drugs mentioned

• SMOFLIPID

Snippet

Sponsor: Mayo Clinic | Conditions: Home Parenteral Nutrition, Short Bowel Syndrome | Phase 4 | Status: WITHDRAWN